- Open Access
Integrative analysis reveals functional and regulatory roles of H3K79me2 in mediating alternative splicing
Genome Medicinevolume 10, Article number: 30 (2018)
Accumulating evidence suggests alternative splicing (AS) is a co-transcriptional splicing process not only controlled by RNA-binding splicing factors, but also mediated by epigenetic regulators, such as chromatin structure, nucleosome density, and histone modification. Aberrant AS plays an important role in regulating various diseases, including cancers.
In this study, we integrated AS events derived from RNA-seq with H3K79me2 ChIP-seq data across 34 different normal and cancer cell types and found the higher enrichment of H3K79me2 in two AS types, skipping exon (SE) and alternative 3′ splice site (A3SS).
Interestingly, by applying self-organizing map (SOM) clustering, we unveiled two clusters mainly comprised of blood cancer cell types with a strong correlation between H3K79me2 and SE. Remarkably, the expression of transcripts associated with SE was not significantly different from that of those not associated with SE, indicating the involvement of H3K79me2 in splicing has little impact on full mRNA transcription. We further showed that the deletion of DOT1L1, the sole H3K79 methyltransferase, impeded leukemia cell proliferation as well as switched exon skipping to the inclusion isoform in two MLL-rearranged acute myeloid leukemia cell lines. Our data demonstrate H3K79me2 was involved in mediating SE processing, which might in turn influence transformation and disease progression in leukemias.
Collectively, our work for the first time reveals that H3K79me2 plays functional and regulatory roles through a co-transcriptional splicing mechanism.
Alternative splicing (AS) is a pre-mRNA process mainly controlled by post-transcriptional regulation involving 90% of human multi-exonic coding genes in a variety of tissues and cell types [1,2,3]. Many studies have highlighted the key role of AS in regulating cellular development and differentiation, and aberrant AS events lead to disease states such as muscular dystrophies and cancers [4,5,6]. Accumulating evidence further supports a new paradigm that AS is a co-transcriptional splicing process mutually coordinated by transcription and splicing [7,8,9]. Recent studies further illustrate that splicing is also regulated by epigenetic regulators, including chromatin structure, histone modifications, and CTCF [10, 11]. Dysregulation of some epigenetic components may alter the splicing process, resulting in various types of human diseases [12,13,14,15]. For instance, a recent study reported that a mutation of the histone methyl transferase SEDT2 alters AS of several key WNT signaling regulatory genes, resulting in colorectal cancer .
Recent genome-wide studies revealed histone marks such as H3K36me3 and H3K79me2 as well as nucleosome positioning were highly enriched within intragenic regions, implicating their regulatory roles in the RNA polymerase II elongation process and exon definition [17,18,19,20]. Further studies demonstrated the enrichment levels of histone modifications were correlated not only with transcriptional activity, but also with AS [21,22,23]. Despite these de novo genome-wide findings, knowledge on the causal and functional roles of histone modifications in AS is limited. In addition, little work has been done on aberrant AS processing in diseases caused by epigenetic defects.
H3K79, located in the globular domain of histone H3, is exposed on the nucleosome surface and then methylated by the sole enzyme DOT1-like histone lysine methyltransferase (DOT1L), a member of the lysine methyltransferase family . This histone methylation typically functions in transcriptional regulation [25, 26], telomeric silencing [27, 28], cell-cycle regulation , and DNA damage repair [30,31,32]. Recent studies revealed a new role for it in regulating AS [33,34,35]. For example, H3K79me2 is able to recruit chromodomain-containing protein MRG15 and splicing factor PTB1 to influence AS outcomes [36, 37]. In particular, new findings demonstrated its crucial role in transformation as well as disease progression in leukemias [38,39,40]. DOT1L is frequently involved in chromosomal translocations, with numerous genes creating fusion genes that interfere with its interaction with the elongation complexes, resulting in a loss of function. This is common in the mixed-lineage leukemia (MLL) gene, resulting in aggressive leukemia , including 5–10% of adult acute leukemias  and 60–80% of infant acute leukemias . These findings have established a foundation for disease-specific epigenetic therapies against acute leukemias.
In a previous study, we found a correlation between H3K79me2 enrichment level and an exon skipping event in GM12878 and K562 cells . However, the common and cell type-specific genomic patterns and correlations between H3K79me2 and various types of splicing events across diverse cell types have not been fully explored. In this study, we integrated AS events derived from RNA-seq with H3K79me2 ChIP-seq data across 34 different normal and cancer cell types, and examine the enrichment of H3K79me2 in five major types of AS events, skipping exon (SE), mutual exclusive exon (MXE), retained intron (RI), alternative 5′-end splice site (A5SS), and alternative 3′-end splice site (A3SS). We attempt to elucidate functional and regulatory roles of H3K79me2 in mediating AS, particularly in MLL-rearranged (MLL-r) acute myeloid leukemia (AML) cells.
Raw data processing
H3K79me2 ChIP-seq and RNA-seq data for a total of 34 various normal and cancer cell lines were collected from the Gene Expression Omnibus (GEO) repository and ENCODE Consortia (Additional file 1: Table S1). Raw sequence reads were aligned against the human genomic sequence (GRCh37) using bowtie2 for ChIP-seq data  and TopHat (version 2.0.14) for RNA-seq data . Only uniquely mapped reads were used for further downstream analysis.
Identification of AS events and H3K79me2 enrichment and peaks
Unique reads from RNA-seq data in bam format are used as input for MISO (The Mixture of Isoforms), which detected AS events based on Bayes factors, filtering criteria, Psi values (Ψ) and confidence intervals . Sashimi plots were generated to illustrate all five types of AS events for visualization. The enrichment of H3K79me2/kb is calculated as the number of reads from H3K79me2 ChIP-seq data in exon skipping gene regions (the exon part of an exon skipping gene plus 50 bp upstream and downstream around exons) per kilobase pair (the length of the exon skipping gene region) normalized by the total number of reads of each dataset. The H3K79me2 peaks were identified by Model-based Analysis of ChIP-Seq version 2 (MACS2) with a q value (minimum false discovery rate (FDR)) of 0.01 .
Self-organizing map clustering
We used self-organizing map (SOM) clustering for dimension reduction for feature extraction associated with exon skipping sites. SOM is a model of two-layer artificial neural networks that maps high dimensional input datasets to a set of nodes arranged in lattice. SOM has two steps: (i) determining a winner node and (ii) updating weighted vectors associated with the winner node and some of its neighboring nodes. According to the enrichment of H3K79me2 for each SE site, the SOM algorithm maps multi-dimensional input vectors to two-dimensional neurons, helping to understand the high-dimensional SE data; the most enriched cluster for each cell is assigned to their cell type. The SOM training was performed using the R package “kohonen”. SOM training parameters and node number optimization were defined on the basis of Xie et al. . Node grouping was based on a hierarchical clustering approach using the hclust function of the “Stats” package of R. The number of clusters was chosen based on homogeneity analyses.
Cell culture and reagents
Human cell lines MV-4-11, K562, and OCI-LY7 were cultured in Iscove’s modified Dulbecco's medium (Thermo Fisher Scientific) and GM12878, MM.1S, and MOLM-14 cell lines were cultured in RPMI-1640/10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA) at 37 °C in 5% CO2. MOLM-14 and OCI-LY7 cells were purchased from the DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany), and GM12878, K562, MM.1S, and MV-4-11 cells were purchased from ATCC (American Type Culture Collection).
Co-transfection and cell viability assay
siRNAs of DOT1L were purchased from Thermo Fisher Scientific Silencer® Select siRNAs. For transfection of siRNA oligos, cells were seeded in six-cell plates with Lipofectamine® RNAiMAX Transfection Reagent for 48 h.
The Cell Counting Kit-8 method was used to measure cell viability. Cells were seeded in 96-well plates at a density of 3 × 103 cells/ml. The viability of cells was assessed using the CCK8 reagent (Dojindo Laboratories, Japan) according to the manufacturer’s protocols. The absorbance at 450 nm was recorded on a microplate reader.
RT-PCR and ChIP-qPCR
Total RNAs from cells were extracted using Quick-RNA™ MiniPrep kit (Zymo Research). Then cDNA was prepared using a RevertAid H Minus First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). The PCR primers for amplifying cDNA fragments between the upstream exon and downstream exon of five exon-skipping event sites are described in Additional file 1: Table S2. PCR was performed with NEBNext® High-Fidelity 2X PCR Master Mix (New England Biolabs, UK), and the cycling conditions were 98 °C for 1 min, then 30 cycles of 98 °C for 10 s, 58 °C for 20 s, 72 °C for 30 s. PCR products were visualized on 3% agarose gels.
ChIP-qPCR was performed as described in Zhu et al. . Briefly, crosslinking was performed with 1% formalin and the cells were lysed in SDS buffer. DNA was fragmented by sonication with a Covaris S220. Chromatin immunoprecipitation (ChIP) was performed using an antibody to the H3K79me2 modification (Abcam, ab3594). Quantification of ChIP-DNA analysis was performed with the LightCycler® 480 SYBR Green I Masteron and LightCycler® 480 System Sequence Detection System (Roche Applied Science) using GAPDH for normalization with primers listed in Additional file 1: Table S3.
Identification of the AS events across 34 normal and cancer cell types
We obtained both RNA-seq and H3K79me2 ChIP-seq data for a total of 34 different cell types with 18 normal and 16 cancer cell types from the GEO repository and ENCODE Consortia (Additional file 1: Table S1). Using the MISO tool and an annotated AS database , we first identified exon junction reads, calculated the ψ-value (Psi, percent splice in) for the number of reads aligned to splice junctions vs target exons (Additional file 2: Figure S1), and finally determined the specific predominant isoform for each of five major types of AS events: SE, MXE, RI, A5SS, A3SS (Fig. 1a). As demonstrated in Fig. 1b for the ψ-value distribution, ψ-value ≤ 0.2 was used to determine the predominant splicing isoform for SE and A3SS, but ψ-value ≥ 0.8 was used for RI and A5SS; however, either ψ-value was used for MXE. Consequently, we identified a total of 41,840 SE, 5228 MXE, 3909 RI, 7386 A3SS, and 7303 A5SS events for all 34 cell types (Fig. 1c), with SE clearly the major splicing event. We applied unsupervised clustering on all AS events to illustrate the difference among samples. Among the three types of cell clusters, most normal cell types, such as fibroblast, myotube, GM12878, and others, showed distinct AS event patterns compared with cancer or blood cancer cell types (Fig. 1d). The numbers of identified AS events were quite diverse in terms of genomic locations and among different cell types, 330–3035 for SE, 0–290 for MXE, 0–249 for RI, 112–301 for A5SS, and 0–345 for A3SS events, respectively (Additional file 2: Figure S2 and Additional file 1: Table S4).
Characterization of H3K79me2 enrichment around splice sites
Our previous data integration revealed strong enrichment of H3K79me2 at exon skipping sites in GM12878 and K562 cells . To extend this observation, we set out to comprehensively characterize H3K79me2 enrichment with each of the five types of AS events. We first examined the average H3K79me2 enrichment for each AS event for the combined set of all 34 cell types. We were particularly interested in understanding the enrichment at the alternative and junction sites of four discrete genomic regions, including 50 bp around the 5′-end of the splice site, 50 bp around the 3′-end of the splice site, 50 bp around the 3′-end of the upstream exon, and 50 bp around the 5′-end of the downstream exon. We also selected a set of non-AS sites randomly from exons and genes without any AS events as a control. Interestingly, we found only two AS event types, SE and A3SS, were highly enriched with H3K79me2 in comparison to non-splice sites (Fig. 2a). For SE, skipping and junction sites exhibited 118 and 64% higher levels of H3K79me2, respectively, than these random non-skipping sites, and for A3SS, alternative 3′ splice sites and the 3′-end of the upstream exon showed dramatic 187 and 367% increases in enrichment, respectively, but only a 21.5% increase for the 5′-end of the downstream exon. We noted that we did not observe any enrichment of H3K79me2 in the other three splicing events (Additional file 2: Figure S3). A close examination of the distribution of H3K79me2 at SE sites showed a diversity of its enrichment levels in each individual cell type (Additional file 2: Figure S4). Further, we identified 33,765 (80.7%) of 41,840 SE sites with higher H3K79me2 enrichment, 10.3% with no significant difference, and 9.0% with decreased enrichment relative to the average H3K79me2 enrichment at non-ES sites. Remarkably, 35.2% of these have an enriched H3K79me2 peak called by MACS2. For A3SS, the numbers were 56.7% (4141 of 7303), 33.0%, and 10.3% with higher, the same, and lower levels of H3K79me2 enrichment compared to non-A3SS sites (Fig. 2b and Additional file 2: Figure S3). We further looked into the AS events with H3K79me2 peaks around the skipped exons and A3SS event start sites. The density plot of the raw read enrichment for each event by z-score normalization within a range of 200 bp upstream and 400 bp downstream showed clear H3K79me2 enrichment around exon junction sites toward the skipped exon in SE events and higher H3K79me2 enrichment around the A3SS event start sites (Fig. 2c). We visually illustrate two examples of RNA-seq and H3K79me2 ChIP-seq data in Fig. 2d, a specific SE event in the ZNF512 gene in GM12878 cells vs non-SE in primary B cells and a A3SS event in the MATR3 gene in skeletal muscle myoblast cells vs non-A3SS in arm fibroblast cells.
SOM clustering for SE sites across 34 different cell types
Since SE is the predominant splicing event and is highly enriched for the H3K79me2 mark, we sought to further characterize the genes or transcripts associated with SE sites to dissect their relationship with cancer cell type specificity. We ranked cell type by H3K79me2 enrichment/kb (see the definition in “Methods”) based on the H3K79me2 enrichment level for a total of 7017 genes associated with ES sites in all 34 cell types. Interestingly, we found that two blood cancer cell lines, MV-4-11 and OCI-LY3, have the highest levels. We then performed SOM clustering on the data with at least 100 iterations and obtained optimized parameters that enabled the assignment of all genes into a 40×25 hexagon matrix and definition of six clusters, A to F (Fig. 3a and Additional file 2: Figure S5). Each of the 34 cell types was able to be assigned into one of the six clusters. We strikingly identified two clusters, A and F, which consisted predominately of cell lines derived from hematological malignancies: cluster A included AML lines MOLM14, MV-4-11, NOMO1, and OCI-LY3 and the chronic myeloid leukemia (CML) line K562; and cluster F included the B-cell non-Hodgkin lymphoma line Karpas-422, multiple myeloma line MM.1S, diffuse large B-cell lymphoma line OCI-LY7, acute lymphoblastic leukemia line SEM, and lymphoblastoid line GM12878 (Fig. 3b). We also found that clusters C and D were mainly composed of various normal cell types. Further, we examined the enrichment of H3K79me2 between SE sites and non-SE sites in each of the six clusters. Remarkably, we found cluster A had the most significant enrichment difference (1.792 log2 fold change, p value < 0.001) and cluster F the second-most (1.671 log2 fold change and p value < 0.01) (Fig. 3c and Additional file 2: Figure S6). Our results clearly demonstrate that H3K79me2 enrichment within splice sites was highly correlated with blood cell types, especially for AML and B-cell lymphoma. In particular, we noticed that the cell types in cluster A are mainly MLL-r cell types (MOLM14 and NOMO1 are MLL-AF9 and MV-4-11 is MLL-AF4). However, only SEM in cluster F is of the MLL-r cell type. Interestingly, several recent studies have demonstrated the functional role of DOT1L in the development and progression in MLL-r type leukemia [39, 50]. Together, our data reveal the potential regulatory or functional contribution of epigenetic-mediated splicing events to progression of this particular disease.
Gene expression, Gene Ontology, and motif analyses of SE-associated genes
To further examine the expression level of transcripts associated with SE sites, we compared transcripts associated with SE sites with a random set of non-SE genes in each of six clusters and didn’t observe any significant difference between any two sets in any of the six clusters (Fig. 4a). This result is not so surprising given SE sites’ known role in the precursor mRNA (pre-mRNA) regulatory stage as opposed to full mRNA translation . However, it does indicate that the involvement of H3K79me2 in splicing might not impact full mRNA expression. Furthermore, we carried out Gene Ontology (GO) term enrichment analysis using EnrichR [52, 53]. We found that genes in clusters A and F were involved in mRNA splicing via spliceosome with a p value < 0.001, as were genes in cluster B (p value 0.026). However, genes in clusters C, D, and E were not associated with any splicing events (Additional file 2: Figure S7). To further examine the pathway analysis, we overlaid 912 SE genes in cluster A and 726 in cluster F and compared these with a public data set of 114 MLL-r target genes enriched with H3K79me2 . Consequently, we identified 767 unique SE genes in cluster A, 583 in cluster F, and 139 overlapping between clusters A and F, as well as 24 genes common to all three data sets (Fig. 4b). We then carried out KEGG pathway analysis for the unique and overlapping genes in clusters A and F. Interestingly, cancer pathways, transcriptional misregulation, spliceosome, AML, and CML were among the top significantly enriched (p value < 0.01) pathways in the overlapping genes between clusters A and F (Fig. 4c).
The trans-acting RNA-binding proteins, often called splicing factors (SFs), play central roles in promoting or suppressing the use of a particular splice site. Thus, we searched for SF or RBP motifs in the sequences spanning skipping sites, 50 bp extending into the exon and intron, using the RBPmaptool, a tool designed to map SF binding sites in human genomic regions using the COS(WR) algorithm . We compared the frequency of predicted SF motifs (SFMs) in the four defined genomic regions immediately adjacent to skipping sites versus non-skipping locations. As shown in Fig. 4d, for the common genes in clusters A and F, the top 30 highly enriched SFMs showed a strong tendency towards being within 50 bp of a skipping exon start site, which are highly involved in the exon junction process. In contrast, for the unique genes identified in clusters A or F, the top enriched SFMs were towards the end of the skipped exon. Interestingly, we found that two enriched motifs, SRSF2 and U2AF2, were previously reported to be highly involved in AML progression through aberrant splicing regulation  and another motif, PTBP1, was shown to play an important role in breast and colorectal cancers [57, 58]. Taken together, our in silico analyses unveil a potential mechanistic or functional link between H3K79me2-mediated skipping exon processing, splicing factors, and disease progression.
Functional characterization of DOT1L-mediated SE in MLL-r AML cells
Recent studies have demonstrated that knockdown of DOT1L effectively reduced the H3K79 methylation level in AML cell lines [29, 59] and impeded leukemia cell proliferation . Since DOT1L is the sole K79me methyltransferase, we reasoned that DOT1L is the major regulator in mediating SE in MLL-r AML progression. To functionally characterize the role of H3K79me2 or DOT1L in mediating SE sites in AML, we conducted several functional assays in two selected MLL-r AML cell lines, MV-4-11 (MLL-AF4) and MOLM14 (MLL-AF9), and a lymphoblastoid cell line, GM12878. DOT1L knockdown by siDOT1L clearly reduced the DOT1L protein level in all three cell lines (Fig. 5a) as well as in another three cell lines, K562, MM.1S, and OCI-LY7 (Additional file 2: Figure S8). This depletion dramatically impeded proliferation in both AML cell lines (P < 0.05 vs control, one-way ANOVA), but not in GM12878 cells (P > 0.05) (Fig. 5b and Additional file 2: Figure S9). We further tested if this depletion of DOT1L would decrease the enrichment level of H3K79me2. To do this, we selected five genes with exon skipping events, MAGOHB, CTBP1, MEIS1, RELA, and THOC1, from the overlapped genes between clusters A and F and unique genes in cluster A. Indeed, the enrichment of H3K79me2 level at ~ 100 bp around the SE start site was decreased at all five sites in three cell lines after DOT1L knockdown (Fig. 5c). These five genes showed SE events in MOLM14, MV-4-11, K562, MM.1S, and GM12878 cell lines but not in the OCI-LY7 cell line. Strikingly, we found that the exon skipped sites were able to switch to exon inclusion in both DOT1L knockdown AML cell lines, suggesting H3K79me2 is involved in the exon skipping process (Fig. 5d and Additional file 2: Figure S10). Although MEIS1 was previously shown to drive MLL-r leukemogenesis through altering DOT1L activity and hypermethylation at H3K79 , our data further suggest that DOT1L-mediated splicing drives this leukemogenesis. In addition, we also validated our assertion by re-analyzing public genome-wide datasets. Interestingly, we observed changes in exon usage from SE to non-SE after DOT1L treatment at three concentrations, 58 genes at 0.5 μM, 60 genes at 1 μM, and 73 genes at 2 μM, with an overlap of 14 genes for all treatments (Additional file 2: Figure S11) . Collectively, our results support novel regulatory and functional roles of H3K79me2 in mediating AS.
The current paradigm of pre-mRNA splicing centers on a post-transcriptional process mediated by the spliceosome machinery . However, accumulating evidence suggests that AS is a co-transcriptional splicing process not only controlled by RNA-binding splicing factors, but also mediated by epigenetic regulators, such as chromatin structure, nucleosome density, and histone modification . Many recent genome-wide studies, including ours, have revealed the regulatory roles of H3K36me3, H3K79me2, and nucleosome positioning in the RNA polymerase II elongation process and exon definition [18,19,20]. To further extend our previous study in which we observed a high enrichment of H3K79me2 at skipped exon sites in GM12878 and K562 cells, we conducted an integrative analysis of RNA-seq and H3K79me2 ChIP-seq data across 34 normal and cancer cell types. Intriguingly, we not only confirmed high enrichment of H3K79me2 in SE type splicing events, but also uncovered its enrichment in A3SS events (Fig. 2a). Further, a large proportion of SE sites are characterized by computationally defined H3K79me2 peaks (Fig. 2b), reflecting the high confidence of regulatory activity of H3K79me2 on the exon skipping process.
One novel finding in this study is the identification of six clusters of cell type-specific enrichment of H3K79me2 at skipping exons among 34 cell types. In particular, we discovered that a pattern of histone marks that promote exon skipping was a common feature in cell lines derived from hematological malignancies, in particular MLL-r AML cell types (Fig. 3b). Indeed, when closely examining this in each individual cell type, we observed a clear separation of enrichment of H3K79me2 in a majority of blood-related cell types (Additional file 2: Figure S3). Our data highlight the importance of H3K79me2 in AS events across different cell types, but most noticeably in blood cells. Previous studies showed that, for specific gene expression, inactivation of DOT1L led to the downregulation of direct MLL-AF9 targets and an MLL translocation-associated gene expression signature [59, 63]. However, in our study, due to a lack of data for DOT1L inhibition for all 34 cell types, we examined the expression level of transcripts associated with SE sites against a random set of non-SE genes in each cell type and did not observe any significant difference in gene expression between these two sets (Fig. 4a), indicating the correlation of H3K79me2 and SE may be independent of gene expression and such correlation might be through a co-transcriptional pre-RNA splicing mechanism. To our knowledge, this is the first comprehensive study to integrate all available matched RNA-seq and H3K79me2 ChIP-seq data in the same cell type. In a broader aspect, such an integrative strategy may provide a general approach for dissecting the relationship of other histone marks or epigenetic factors with the splicing process and further uncover their novel functionalities associated with various diseases or cancer types, providing a rationale to further explore the underlying mechanism for AML patients without mutations or independent of gene expression.
The gene enrichment and pathway analyses further revealed that H3K79me2-mediated exon skipping-associated genes were highly involved in acute or chronic myeloid leukemia cell types, underscoring their functional relevance to blood cancer progression. Indeed, the various functional assays in this study confirmed that such exon skipping events were highly coordinated by the H3K79me2 or DOT1L activities with DOT1L siRNA treatment in two MLL-r AML cell lines (Fig. 5), providing a new line of evidence of a co-transcriptional splicing process involved in AML. Other studies have shown that higher levels of H3K79me2 are associated with poorer prognosis in MLL-r leukemias , and the fusion of DOT1L and MLL partners, AF4, AF9, ENL, and AF10, leads to misregulation of DOT1L targets, resulting in aberrant H3K79me2 activity followed by leukemic transformation [64, 65]. However, our results further unveiled new regulatory and functional roles of H3K79me2 in determining transcript isoforms, providing a mechanistic link between H3K79me2 or DOT1L and splicing events in this particular disease progression.
Our findings may provide a new avenue and opportunity to develop novel combinatorial therapeutic drugs targeting both epigenetic mechanisms and splicing processes. EPZ-5676, a small-molecule inhibitor of DOT1L, is currently under clinical investigation for acute leukemias harboring rearrangements of the MLL gene. Although the agent effectively targets the DOT1L molecule in vitro, the results of a phase 1 clinical trial were disappointing due to low bioavailability and frequent adverse events . In light of this finding, we may consider in future studies testing a co-treatment model which adds the inhibition of a splicing factor as a second synergistic agent, which may enhance efficacy for treating this deadly disease.
Our study identifies for the first time at a genome-wide scale cell type-specific correlation between H3K79me2 enrichment and skipped exons. This correlation is further utilized to classify the diverse cell types into six distinct clusters. Experimental assays confirm H3K79me2’s functional and regulatory roles in AML disease progression. Our work provides more insights into underlying epigenetic regulatory mechanisms in the co-transcriptional AS process in normal or disease conditions.
Alternative 3′ splice site
Alternative 5′-end splice site
Acute myeloid leukemia
DOT1-like histone lysine methyltransferase
Mixture of isoforms
Mutually exclusive exon
Splicing factor motifs
Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008;40(12):1413–5.
Nilsen TW, Graveley BR. Expansion of the eukaryotic proteome by alternative splicing. Nature. 2010;463(7280):457–63.
da Costa PJ MJ, Romão L. The role of alternative splicing coupled to nonsense-mediated mRNA decay in human disease. Int J Biochem Cell Biol. 2017;91(Pt B):168–75.
Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, Haverty PM, et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res. 2012;22(12):2315–27.
Santoro M, Masciullo M, Bonvissuto D, Bianchi ML, Michetti F, Silvestri G. Alternative splicing of human insulin receptor gene (INSR) in type I and type II skeletal muscle fibers of patients with myotonic dystrophy type 1 and type 2. Mol Cell Biochem. 2013;380(1-2):259–65.
Walter KR, Goodman ML, Singhal H, Hall JA, Li T, Holloran SM, et al. Interferon-Stimulated Genes Are Transcriptionally Repressed by PR in Breast Cancer. Mol Cancer Res. 2017;15(10):1331–40.
Roberts GC, Gooding C, Mak HY, Proudfoot NJ, Smith CW. Co-transcriptional commitment to alternative splice site selection. Nucleic Acids Res. 1998;26(24):5568–72.
Listerman I, Sapra AK, Neugebauer KM. Cotranscriptional coupling of splicing factor recruitment and precursor messenger RNA splicing in mammalian cells. Nat Struct Mol Biol. 2006;13(9):815–22.
Luco RF, Allo M, Schor IE, Kornblihtt AR, Misteli T. Epigenetics in alternative pre-mRNA splicing. Cell. 2011;144(1):16–26.
Trincado JL, Sebestyén E, Pagés A, Eyras E. The prognostic potential of alternative transcript isoforms across human tumors. Genome Med. 2016;8(1):85.
Agirre E, Bellora N, Alló M, Pagès A, Bertucci P, Kornblihtt AR, et al. A chromatin code for alternative splicing involving a putative association between CTCF and HP1α proteins. BMC Biol. 2015;13:31.
Zhu L, Wang X, Li XL, Towers A, Cao X, Wang P, et al. Epigenetic dysregulation of SHANK3 in brain tissues from individuals with autism spectrum disorders. Hum Mol Genet. 2014;23(6):1563–78.
Verma A, Jiang Y, Du W, Fairchild L, Melnick A, Elemento O. Transcriptome sequencing reveals thousands of novel long non-coding RNAs in B cell lymphoma. Genome Med. 2015;7:110.
Li T, Xu X, Li J, Xing S, Zhang L, Li W, et al. Association of ACP1 gene polymorphisms and coronary artery disease in northeast Chinese population. J Genet. 2015;94(1):125–8.
Ntziachristos P, Abdel-Wahab O, Aifantis I. Emerging concepts of epigenetic dysregulation in hematological malignancies. Nat Immunol. 2016;17(9):1016–24.
Yuan H, Li N, Fu D, Ren J, Hui J, Peng J, et al. Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis. J Clin Invest. 2017;127(9):3375–91.
Kolasinska-Zwierz P, Down T, Latorre I, Liu T, Liu XS, Ahringer J. Differential chromatin marking of introns and expressed exons by H3K36me3. Nat Genet. 2009;41(3):376–81.
Andersson R, Enroth S, Rada-Iglesias A, Wadelius C, Komorowski J. Nucleosomes are well positioned in exons and carry characteristic histone modifications. Genome Res. 2009;19(10):1732–41.
Sveen A, Agesen TH, Nesbakken A, Rognum TO, Lothe RA, Skotheim RI. Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival. Genome Med. 2011;3(5):32.
Ye Z, Chen Z, Lan X, Hara S, Sunkel B, Huang TH, et al. Computational analysis reveals a correlation of exon-skipping events with splicing, transcription and epigenetic factors. Nucleic Acids Res. 2014;42(5):2856–69.
Spies N, Nielsen CB, Padgett RA, Burge CB. Biased chromatin signatures around polyadenylation sites and exons. Mol Cell. 2009;36(2):245–54.
de Almeida SF, Grosso AR, Koch F, Fenouil R, Carvalho S, Andrade J, et al. Splicing enhances recruitment of methyltransferase HYPB/Setd2 and methylation of histone H3 Lys36. Nat Struct Mol Biol. 2011;18(9):977–83.
Zhang X, Zhao D, Xiong X, He Z, Li H. Multifaceted histone H3 methylation and phosphorylation readout by the plant homeodomain finger of human nuclear antigen Sp100C. J Biol Chem. 2016;291(24):12786–98.
Feng Q, Wang H, Ng HH, Erdjument-Bromage H, Tempst P, Struhl K, et al. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol. 2002;12(12):1052–8.
Steger DJ, Lefterova MI, Ying L, Stonestrom AJ, Schupp M, Zhuo D, et al. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol Cell Biol. 2008;28(8):2825–39.
Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008;40(7):897–903.
Kimura A, Umehara T, Horikoshi M. Chromosomal gradient of histone acetylation established by Sas2p and Sir2p functions as a shield against gene silencing. Nat Genet. 2002;32(3):370–7.
Suka N, Luo K, Grunstein M. Sir2p and Sas2p opposingly regulate acetylation of yeast histone H4 lysine16 and spreading of heterochromatin. Nat Genet. 2002;32(3):378–83.
Kim W, Kim R, Park G, Park JW, Kim JE. Deficiency of H3K79 histone methyltransferase Dot1-like protein (DOT1L) inhibits cell proliferation. J Biol Chem. 2012;287(8):5588–99.
Huyen Y, Zgheib O, Ditullio RA, Gorgoulis VG, Zacharatos P, Petty TJ, et al. Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks. Nature. 2004;432(7015):406–11.
Wysocki R, Javaheri A, Allard S, Sha F, Côté J, Kron SJ. Role of Dot1-dependent histone H3 methylation in G1 and S phase DNA damage checkpoint functions of Rad9. Mol Cell Biol. 2005;25(19):8430–43.
Li J, Liu X, Chu H, Fu X, Li T, Hu L, et al. Specific dephosphorylation of Janus Kinase 2 by protein tyrosine phosphatases. Proteomics. 2015;15(1):68–76.
Zhou HL, Hinman MN, Barron VA, Geng C, Zhou G, Luo G, et al. Hu proteins regulate alternative splicing by inducing localized histone hyperacetylation in an RNA-dependent manner. Proc Natl Acad Sci U S A. 2011;108(36):E627–35.
Long L, Thelen JP, Furgason M, Haj-Yahya M, Brik A, Cheng D, et al. The U4/U6 recycling factor SART3 has histone chaperone activity and associates with USP15 to regulate H2B deubiquitination. J Biol Chem. 2014;289(13):8916–30.
Liu Q, Bonneville R, Li T, Jin VX. Transcription factor-associated combinatorial epigenetic pattern reveals higher transcriptional activity of TCF7L2-regulated intragenic enhancers. BMC Genomics. 2017;18(1):375.
Singh NN, Lawler MN, Ottesen EW, Upreti D, Kaczynski JR, Singh RN. An intronic structure enabled by a long-distance interaction serves as a novel target for splicing correction in spinal muscular atrophy. Nucleic Acids Res. 2013;41(17):8144–65.
Xu Y, Gan ES, Zhou J, Wee WY, Zhang X, Ito T. Arabidopsis MRG domain proteins bridge two histone modifications to elevate expression of flowering genes. Nucleic Acids Res. 2014;42(17):10960–74.
Nguyen AT, Zhang Y. The diverse functions of Dot1 and H3K79 methylation. Genes Dev. 2011;25(13):1345–58.
Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA, et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013;122(6):1017–25.
Deshpande AJ, Deshpande A, Sinha AU, Chen L, Chang J, Cihan A, et al. AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell. 2014;26(6):896–908.
Ayton PM, Cleary ML. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene. 2001;20(40):5695–707.
Daser A, Rabbitts TH. Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. Genes Dev. 2004;18(9):965–74.
Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7(11):823–33.
Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9(4):357–9.
Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 2013;14(4):R36.
Katz Y, Wang ET, Airoldi EM, Burge CB. Analysis and design of RNA sequencing experiments for identifying isoform regulation. Nat Methods. 2010;7(12):1009–15.
Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9(9):R137.
Xie D, Boyle AP, Wu L, Zhai J, Kawli T, Snyder M. Dynamic trans-acting factor colocalization in human cells. Cell. 2013;155(3):713–24.
Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M, Getlik M, et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature. 2015;525(7568):206–11.
Chen CW, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, et al. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. Nat Med. 2015;21(4):335–43.
Keren H, Lev-Maor G, Ast G. Alternative splicing and evolution: diversification, exon definition and function. Nat Rev Genet. 2010;11(5):345–55.
Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128.
Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1):W90–7.
Wang QF, Wu G, Mi S, He F, Wu J, Dong J, et al. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood. 2011;117(25):6895–905.
Paz I, Kosti I, Ares M, Cline M, Mandel-Gutfreund Y. RBPmap: a web server for mapping binding sites of RNA-binding proteins. Nucleic Acids Res. 2014;42(Web Server issue):W361–7.
Landau DA, Wu CJ. Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Med. 2013;5(5):47.
He X, Arslan AD, Ho TT, Yuan C, Stampfer MR, Beck WT. Involvement of polypyrimidine tract-binding protein (PTBP1) in maintaining breast cancer cell growth and malignant properties. Oncogene. 2014;3:e84.
Takahashi H, Nishimura J, Kagawa Y, Kano Y, Takahashi Y, Wu X, et al. Significance of polypyrimidine tract-binding protein 1 expression in colorectal cancer. Mol Cancer Ther. 2015;14(7):1705–16.
Kerry J, Godfrey L, Repapi E, Tapia M, Blackledge NP, Ma H, et al. MLL-AF4 spreading identifies binding sites that are distinct from super-enhancers and that govern sensitivity to DOT1L inhibition in leukemia. Cell Rep. 2017;18(2):482–95.
Riedel SS, Haladyna JN, Bezzant M, Stevens B, Pollyea DA, Sinha AU, et al. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. J Clin Invest. 2016;126(4):1438–50.
Ilagan JO, Ramakrishnan A, Hayes B, Murphy ME, Zebari AS, Bradley P, et al. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res. 2015;25(1):14–26.
Braunschweig U, Barbosa-Morais NL, Pan Q, Nachman EN, Alipanahi B, Gonatopoulos-Pournatzis T, et al. Widespread intron retention in mammals functionally tunes transcriptomes. Genome Res. 2014;24(11):1774–86.
Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011;20(1):66–78.
Mueller D, Bach C, Zeisig D, Garcia-Cuellar MP, Monroe S, Sreekumar A, et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood. 2007;110(13):4445–54.
Mohan M, Herz HM, Takahashi YH, Lin C, Lai KC, Zhang Y, et al. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev. 2010;24(6):574–89.
We are grateful to all members of the Jin laboratories for valuable discussion.
This study is partially supported by NIH R01GM114142 and U54CA217297, as well as Owens foundation. Funding for open access charge: NIH. The authors gratefully acknowledge financial support from Scholarship of Jilin University.
Availability of data and materials
All data generated during this study are included in this published article and the additional files.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.